Aim: To investigate the effect of selenium supplementation at different dose levels on changes in HbA1c after 6 months and 2 years in a population of low selenium status.
observational studies and randomized clinical trials have raised concerns that high Se exposure may lead to adverse cardio-metabolic effects, including an increased risk of type 2 diabetes in Se-replete populations such as the United States. [2] [3] [4] Indeed, in a post hoc analysis of the Nutritional Prevention of Cancer (NPC) trial in the eastern United States, we found Se supplementation (200 μg/d), compared to placebo, increased the risk of type 2 diabetes, particularly among individuals with high baseline plasma Se. 5 In addition, a number of selenoproteins, primarily selenoprotein P (SEPP1) and glutathione peroxidase (GPx1), have been linked with diabetogenic effects. [6] [7] [8] [9] There are gaps in the current available evidence. First, many of the observational studies are cross-sectional surveys or prospective investigations based on a single analysis of Se status at one time point only, and are therefore subject to reverse causation and incidence/ prevalence biases. [10] [11] [12] [13] Second, there have been disappointing findings from several costly clinical trials of antioxidant supplements
showing not only an absence of health benefits but also potential harm. 5, [14] [15] [16] [17] [18] Third, most previous research in this area has been conducted in North American populations where baseline Se status is substantially higher than in Europe. Dietary intakes of Se vary considerably between countries and regions, mainly because of the variability of the Se content of plant foods (and hence of animal forage) from one part of the world to another. 1, 19 We determined the effect of different doses of Se supplementation (100, 200 and 300 μg/d or placebo) on HbA1c levels after 6 months and 2 years in a double-blind, randomized, controlled trial in Denmark, a country with lower Se status than that of the United
States. 18, 20 Double-blind, placebo-controlled randomized clinical trials are less prone to many types of biases than observational studies, and provide the strongest level of evidence on the effect of dietary interventions on health outcomes.
| MATERIALS AND METHODS

| Study design and sample size
The Denmark PREvention of Cancer by Intervention with SElenium (PRECISE) pilot study (ClinicalTrials.gov ID: NCT01819649) was a single-centre, randomized, double-blinded, placebo-controlled, multiarm, parallel clinical trial with four groups (allocation ratio 1:1:1:1) run from Odense University Hospital, Denmark. 18, 21, 22 Denmark PRECISE was one of two pilot studies for the proposed international PRECISE trial of Se in cancer prevention; the other was carried out in the UK. 23, 24 No formal power calculations were performed a priori; the sample size was set at 500 participants, which was considered sufficient to assess whether recruitment, adherence and retention during follow-up would be sufficient for a large trial. Randomization was computer-generated, blocked and non-stratified. 18, 21, 22 Participating couples living at the same address were allocated to the same intervention. Participants, research staff and investigators were blinded to treatment assignment. 18, 21, 22 Participants deemed suitable for inclusion provided blood samples and were given yeast tablets for an open-label, 4-week, placebo run-in phase.
Those (n = 491) who met the inclusion criteria, displayed good adherence in the placebo run-in phase, and gave written, informed consent, Hospital at baseline, 6, 12, 18 months, 2, 3 and 5 years, as previously described in detail. 18, 21, 22 The intervention was delivered for 5 years and participants were followed up, post-treatment, for an additional 10 years for mortality ascertainment.
The regional Data Protection Agency and Scientific Ethics Committees of Vejle and Funen counties approved the study prior to data collection (journal number 19980186).
| Baseline measurements
Demographic characteristics, smoking status, height, weight and supplement use were collected at baseline. Medications used were obtained from medical records. Morbidity data were obtained from the Danish National Patient Registry, which has records of major and secondary diagnoses for all inpatient discharges since 1977, and all emergency and outpatient contacts since 1995. 25 The Charlson comorbidity index was computed by adding 19 comorbid conditions diagnosed prior to randomization. 26 
| Selenium measurement
As previously described in detail, 18, 21, 22 total Se was measured gravimetrically (ng/g) in lithium-heparin plasma at LGC Limited (Teddington, UK) by inductively coupled-plasma mass spectrometry at baseline, 6 months and 5 years. Analysis of a matrix-certified reference material indicated good accuracy of the method. The intra-assay coefficients of variation (CVs) ranged from 0.5% for samples of highSe concentration to 3% for samples of low-Se concentration. The inter-assay CV was 3.4%.
| HbA1c measurement
HbA1c at baseline and at the 6-month and 2-year visits was measured in 
| Power calculations for intention-to-treat analysis
The two study endpoints were the differences in HbA1c concentration in each intervention group compared with placebo at 6 months and 2 years of follow-up. For the average sample size of 117 participants retained in each treatment group after 6 months of follow-up and a two-sided significance level of 0.05, the power to detect 
| Statistical analysis
For the analysis of randomized groups, all trial participants were assigned to their randomized treatment group, irrespective of HbA1c levels (intercepts) and HbA1c changes over follow-up (time slopes). The model is specified in detail in the statistical appendix (see Appendix S1). Treatment effects were estimated as the differences in mean HbA1c changes from baseline to 6 months and 2 years comparing the three active treatment groups with placebo. In sensitivity analyses, we excluded visits after participants received diabetes medications at baseline or during the intervention period.
We also evaluated treatment-effect modifications across prespecified subgroups defined by baseline age (< or ≥65 years), sex, smoking status (non-current or current), alcohol drinking (≤ or >2 drinks/wk), body mass index (< or ≥25 kg/m 2 ), baseline plasma Se (< or ≥80 ng/g) and baseline HbA1c (< or ≥42 mmol/mol) by including all main terms and interactions between treatment groups, time, and the corresponding covariate as fixed effects in the above mixed model.
In addition to the intention-to-treat analysis, we evaluated the cross-sectional association of plasma Se and HbA1c levels at baseline and the longitudinal association between changes in plasma Se and HbA1c levels after 6 months (plasma Se measurements were not available at 2 years). As described in the statistical appendix, we used a linear mixed model 22, 23, 28 with random intercepts, random time slopes and fixed slopes for baseline Se levels and Se changes at 6 months to estimate the mean difference in baseline HbA1c levels per 50-ng/g increase in baseline Se levels (cross-sectional association), as well as the difference in mean HbA1c changes from baseline to 6 months for each 50-ng/g change in Se levels (longitudinal association 
counter Se was deemed to be rare because only one of the 108 participants allocated to placebo (0.9%) had plasma Se concentrations more than two standard deviations above the mean at 6 months. Six participants were receiving diabetes medications at baseline, six at 6 months, and 14 at 2 years, with no significant differences between treatment groups at any time (P = 0.70, 0.73 and 0.12, respectively).
| Analysis of randomized groups
The tively, but were virtually unchanged in the placebo group (P < 0.001
for homogeneity of changes across the four groups).
However, small changes in HbA1c were observed in the treatment groups after 6 months of intervention (Table 2) . Compared with placebo, mean HbA1c differences (95% CIs) at 6 months were −1. 
were no significant treatment-effect modifications at 6 months by participant characteristics (Figure 2 ), although 300 μg/d of Se supplementation showed larger HbA1c decreases in participants with lower plasma Se concentrations and prediabetes HbA1c levels at baseline.
After 2 years, HbA1c decreased significantly in the four treatment groups but there were no significant differences between active treatment groups and placebo (Table 2) Change from baseline to 6 months (95% 
| Association between plasma selenium and HbA1c levels
In cross-sectional analyses at baseline, plasma Se concentrations were not associated with HbA1c levels (Table 3) (Table 4) .
| Adverse events
Eight participants died during the 2-year follow-up period and 21 participants discontinued the study because of non-fatal adverse events (Figure 1) , with no significant differences between treatment groups (P = 0.75 and 0.25, respectively). Eighteen participants withdrew because of adverse reactions to treatment (Figure 1 ), which were mainly hair loss, skin reactions and grooved nails. These reactions were equally distributed across placebo and the three active treatment groups (P = 0.63).
| DISCUSSION
Overall, findings from the Denmark PRECISE trial do not support a beneficial or harmful effect of Se supplements on glucose metabolism.
Specifically, in this European population of elderly individuals of low Se status, supplementation at different dose levels of Se did not FIGURE 2 Differences in mean HbA1c changes after 6 months comparing the three active treatment groups with placebo by prespecified baseline subgroup. Subgroup-specific differences in mean HbA1c changes (squares with area inversely proportional to the variance) and their 95% CIs (horizontal lines) were obtained from linear mixed models with fixed interactions between treatment group, time, and the corresponding baseline covariate and random between-subject variations in both baseline HbA1c levels and HbA1c changes over time significantly affect HbA1c levels after 2 years of supplementation.
However, compared to placebo, small beneficial changes in HbA1c
were observed in the treatment groups after 6 months of intervention, particularly at the lowest dose level of Se supplementation (100 μg/d).
The latter finding seems to corroborate the notion of a U-shaped association of Se status and supplementation with glucose metabolism, and possibly other health outcomes. [1] [2] [3] [4] 29 Evidence from in vivo and in vitro studies suggests that Se could enhance insulin sensitivity by mediating insulin-like actions. The overall trial evidence on the effect of Se supplementation on diabetes risk was pooled together by our group in a Cochrane review. 29 We found a small increased risk of type 2 diabetes with Se supplementation, which did not reach statistical significance (RR 1.06, 95% CI 0.97-1.15). However, that review included only the limited number of randomized clinical trials that administered Se alone, all carried out in US populations. 29 In European populations, where Se status is generally lower than in the United States, the evidence linking Se to glucose metabolism is con-
flicting. For example, in an early analysis of the Epidemiology of Vascular
Ageing (EVA) study in France, plasma Se concentrations were positively, although non-significantly, associated with baseline glucose levels in women and with prevalent diabetes in men. 12 However, a later report from the same study showed that high plasma Se (1.19-1.97 μmol/L) was associated with a marginally significant reduced risk of hyperglycaemia (impaired fasting glucose or diabetes) in men over the 9-year followup. 31 Conversely, in a prospective study on a large sample of women from northern Italy, an increased risk of type 2 diabetes was associated with higher dietary Se intake; however, it has to be admitted that dietary assessments of Se intake are unreliable, so less significance can be attached to this result. 13 With regard to trial evidence, in the French SU.VI.MAX study, no effect of combined supplementation with antioxidants including Se (100 μg/d as high-Se yeast) was observed on fasting plasma glucose *Overall P value comparing the three highest quartiles of selenium change with the lowest quartile. a Results were obtained from linear mixed models with random between-subject variations in both baseline HbA1c levels and HbA1c changes over time and adjusted for baseline selenium concentration (continuous), age (continuous), sex, smoking status (never, former or current), alcohol drinking (≤2, 3-10 or >10 drinks/wk), body mass index (continuous), and use of diabetes medications.
FIGURE 3
Changes in HbA1c levels after 6 months by change in plasma selenium concentration. The curve represents mean changes in HbA1c levels from baseline to 6 months (solid line) and their 95% CIs (shaded region) based on restricted quadratic splines for changes in plasma selenium concentrations with knots at the 5th, 50th and 95th percentiles (−11, 81 and 217 ng/g, respectively). Results were obtained from a linear mixed model with random between-subject variations in both baseline HbA1c levels and HbA1c changes over time and adjusted for baseline selenium levels (continuous), age (continuous), sex, smoking status (never, former or current), alcohol drinking (≤2, 3-10 or >10 drinks/wk), body mass index (continuous) and use of diabetes medications. Scatterplot represents changes in plasma selenium and HbA1c levels after 6 months for participants randomized to placebo (green dots), 100 μg/d (blue dots), 200 μg/d (orange dots) and 300 μg/d (red dots) of selenium supplementation after 7.5 years of follow-up despite a positive association between glucose and Se concentrations at baseline in the whole population. 32 More recently, in the UK PRECISE trial among 501 elderly volunteers treated for 6 months with 100, 200 or 300 μg Se/day as high-Se yeast or placebo yeast, we found no effect of Se supplementation on plasma adiponectin, a surrogate marker of type 2 diabetes risk. 24 Findings from the Denmark PRECISE trial seem to suggest that Se supplementation is unlikely to impair glucose metabolism and increase diabetes risk in populations of low Se status. Moreover, small beneficial changes in HbA1c were observed in the treatment groups after 6 months of intervention, particularly at the lowest dose level of Se supplementation (100 μg/d), which is in line with a possible U-shaped relationship between selenium and glucose metabolism. [1] [2] [3] [4] 29 In general, the degree to which populations are adequately supplied with a nutrient is more variable for Se than for many nutrients.
Because of wide differences in geology, soil and climatic factors, foods and fodder from different parts of the world vary greatly in their ability to provide Se for dietary intake. 4 Thus, intake ranges from deficient to excessive in China, is generally low in Europe, adequate in North America and Japan, and is high in Venezuela. 4 Se status -often measured as serum, plasma or toenail Se -varies accordingly, reflecting the difference in intake in these locations. 4 Therefore, the geographic variations in Se intake and status across countries and populations probably represent one plausible explanation for the discrepant results in the published literature.
In terms of potential mechanisms to justify a role of Se in glucose metabolism, in vivo and in vitro studies have shown antidiabetic and insulin mimetic effects of Se (generally as selenate) 30 ; however, doses have been used that would be toxic to humans, calling into question the relevance of these findings.
7,33
Type 2 diabetes is associated with oxidative stress attributable to the production of excess levels of reactive oxygen species in hyperglycaemia. 34 As pancreatic β cells are poorly protected by intrinsic enzymatic antioxidants and are very susceptible to oxidative injury, it might be thought that the antioxidant selenoenzyme, GPx, could protect against that stress. 34 Indeed, overexpression of GPx in islets provided enhanced protection against oxidative stress, 34 while Se, as selenite or selenate at physiological levels, was able to stimulate pancreatic β-cell gene expression and enhance islet function. 35 Whether as cause or consequence, plasma GPx3 concentration was found to be decreased in newly diagnosed, drug-naïve diabetic patients compared with subjects with normal or impaired glucose tolerance, and was lower in db/db mice than in normal mice. 36 Another selenoprotein, SELENOS, appears to protect the β cell against endoplasmic reticulum (ER) stress and oxidative stress, and may protect against β-cell apoptosis. 37 The binding of insulin to its receptor initiates the insulin-signalling cascade, which is accompanied by a burst of hydrogen peroxide that acts as a second messenger. 7 The high activity of (cytosolic) GPx1 can interfere with insulin signalling by removing hydrogen peroxide. 38 Thus, transgenic mice overexpressing GPx1 developed insulin resistance, hyperglycaemia, hyperinsulinaemia and obesity, 38, 39 while knockout of GPx1 improved insulin-induced glucose uptake and insulin resistance. 40 SELENOP has also been implicated in insulin resistance. 6 In vitro, in the presence of insulin, SELENOP modulated insulin signalling to upregulate mRNA expression of gluconeogenic enzymes, resulting in a 30% increase in glucose release. Treatment of mice with purified SELENOP impaired insulin signalling in liver and skeletal muscle and induced glucose intolerance. 6 Conversely, knockdown of the gene for SELENOP in liver improved glucose tolerance and reduced insulin resistance in mice with type 2 diabetes while mice deficient in SELE-NOP showed improved glucose tolerance and enhanced insulin signalling. 6 It is thought that the effect of SELENOP is at least partly through the inactivation of AMP-activated protein kinase, a positive regulator of insulin synthesis and secretion in pancreatic β-cells.
6
Our study has limitations: (a) changes in HbA1c were not the primary endpoint of the Denmark PRECISE trial, hence the need for cautious interpretation of our findings, as they result from post hoc analyses; (b) it was conducted in apparently healthy elderly subjects, so the results may not extend to other age groups or participants with different comorbidities; (c) 71 participants dropped out before completing the 2-year intervention period, although they were equally distributed between treatment groups and captured in the intentionto-treat mortality analysis; and (d) follow-up was only for 6 months and 2 years, which may not have been long enough to see an effect.
Importantly, the role of chance in our findings cannot be ruled out as the sample size was small and the study was not designed to assess the effect of Se supplementation on HbA1c.
In conclusion, our findings add to the limited trial evidence on the effect of Se, as a single agent at different dose levels, on diabetes risk, in a non-Se-replete population, as most of the previous evidence was based on randomized clinical trials conducted among US populations. 5, 15, 16, 29 Overall, our results are reassuring as they do not support potential harmful effects of Se supplements on glucose metabolism in populations of low Se status. Further research is needed to identify the optimal range of Se intake and status in order to minimize potential adverse effects on glucose metabolism while optimizing type 2 diabetes prevention. 4 
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